NBE Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 21
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $1.4B
Latest Deal Amount

NBE Therapeutics General Information

Description

Developer of an immune-stimulatory antibody-drug conjugate platform designed to improve the treatment options for cancer patients. The company's platform creates highly potent and safe immune-stimulatory ADCs with an anthracycline payload, inducing a long-lasting immunological anti-tumor effect, enabling healthcare professionals to avail advanced drugs for more effective results.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Boehringer Ingelheim
Primary Office
  • Technology Park Basel
  • Hochbergstrasse 60C
  • 4057 Basel
  • Switzerland
+41 061 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NBE Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 01-Dec-2020 $1.4B 000.00 00.00 Completed Pre-Clinical Trials
8. Later Stage VC (Series C) 10-Jan-2020 0000 000.00 Completed Pre-Clinical Trials
7. Later Stage VC (Series B) 28-Jun-2018 000.00 000.00 Completed Startup
6. Early Stage VC 01-Nov-2016 00.000 000.00 000.00 Completed Startup
5. Early Stage VC 11-Feb-2016 00.000 00.000 000.00 Completed Startup
4. Grant 05-Jan-2016 00.00 00.000 Completed Startup
3. Early Stage VC (Series A) 20-Feb-2015 00.000 00.000 00.00 Completed Startup
2. Grant 15-Mar-2014 $4.53M $2.76M Completed Startup
1. Seed Round 13-Dec-2013 $2.76M $2.76M Completed Startup
To view NBE Therapeutics’s complete valuation and funding history, request access »

NBE Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference 00,000 000.00 000.00 00 000.00 00.00
Preference 00,000 000.00 000.00 00 000.00 00.000
Preference 80,000 $6.91 $6.91 1x $6.91 25.79%
To view NBE Therapeutics’s complete cap table history, request access »

NBE Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an immune-stimulatory antibody-drug conjugate platform designed to improve the treatment options for cancer
Drug Discovery
Basel, Switzerland
21 As of 2021
000.00
0.00 0000-00-00
000000&0 000.00

00000000

smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000 000000000
Saint Louis, MO
0 As of 0000
000.00
00000000000 000.00

000000 0

m ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et d
0000 000000000
Zurich, Switzerland
00 As of 0000
000.00
000000 0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NBE Therapeutics Competitors (59)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunophotonics Venture Capital-Backed Saint Louis, MO 0 000.00 00000000000 000.00
000000 0000000 Venture Capital-Backed Zurich, Switzerland 00 000.00 000000 0
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 Venture Capital-Backed Basel, Switzerland 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
You’re viewing 5 of 59 competitors. Get the full list »

NBE Therapeutics Patents

NBE Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3647419-A1 Sortase f and its use in methods for conjugation Withdrawn 02-Nov-2018 00000000 0
EP-3874038-A1 Sortase f and its use in methods for conjugation Pending 02-Nov-2018 00000000
EP-3636284-A1 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications Withdrawn 11-Oct-2018 00000000000 0
EP-3863681-A1 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications Pending 11-Oct-2018 00000000000
AU-2019358518-A1 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications Pending 11-Oct-2018 A61K47/6809

NBE Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Ulf Grawunder Ph.D Founder, Chief Executive Officer & Board Member
Bertrand Damour Chief Executive Officer
Roger Beerli Ph.D Chief Scientific Officer
You’re viewing 3 of 6 executive team members. Get the full list »

NBE Therapeutics Board Members (11)

Name Representing Role Since
Ulf Grawunder Ph.D NBE Therapeutics Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 1 of 11 board members. Get the full list »

NBE Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NBE Therapeutics Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
PPF Group PE/Buyout Majority 000 0000 000000 0
Swiss Federal Commission for Innovation and Technology Government 000 0000 000000 0
Venture Kick Accelerator/Incubator Minority 000 0000 000000 0
To view NBE Therapeutics’s complete investors history, request access »